Houston-founded Ema, an AI resource for maternal health support, has been loaded onto the Willow Innovations Inc. app, a platform for breastfeeding mothers. Photo courtesy of Willow

Willow users, meet Ema — you're new best AI-enabled friend.

Houston-founded Ema (née SocialMama), an AI resource for maternal health support, has been loaded onto the Willow Innovations Inc. app, a platform for breastfeeding mothers.

"We are thrilled to integrate our conversational AI platform into the Willow App and leverage the power of advanced technology to meet women where they are with the information they need," Amanda Ducach, founder of Ema, says in a news release. "Ema and Willow have a shared mission to make lasting improvements in women's health and we built a one-of-a-kind solution that addresses the unique challenges mothers face regularly.

"Our partnership represents a critical advancement for today's mothers and demonstrates how responsible AI can improve the maternal care experience," she continues.

Now, users on the app can utilize Ema's HIPPA-secure tool that pulls from a comprehensive, proprietary database of expert-backed information. The conversational AI chatbot responds prioritizing speed, accuracy, and empathy and compassion for users. Ema reports that their users "will feel like they are talking with their favorite postpartum (labor and delivery) nurse."

"New moms don't have enough support — for their feeding and parenting journey, or in their postpartum care. We're thrilled to partner with Ema to offer moms personalized information along this journey," adds Sarah O'Leary, CEO of Willow. "AI tools, when implemented thoughtfully, can help close gaps in delivering personalized guidance at an efficient scale and I'm excited about the impact Ema can have on the well-being of mothers in our Willow community."

Founded in 2018 as a way to connect new moms, Ema evolved with a major rebrand and pivot to AI-backed tools last year.

Willow was launched in 2014 and released the first wearable, in-bra breast pump in 2017.

After growing in Chicago and raising funding, Partum Health selected Houston to expand its femtech platform. Photo via Getty Image

Growing femtech company chooses Houston for first out-of-state expansion

moving in

A startup dedicated to comprehensive pregnancy, birth and postpartum care has expanded from its Chicago birthplace to Houston.

Last summer, Partum Health raised $3.1 million in seed funding, which makes it possible for the company to begin a nationwide expansion. That begins in Space City.

“We looked at states where there is work to do on outcomes for maternal health. Texas rose to the top and Houston, in many ways is fairly close to Chicago, our home city. The really thriving healthcare ecosystem attracted us as well,” CEO and Co-Founder Meghan Doyle tells InnovationMap.

As a mom of a seven-year-old and a nine-year-old herself, Doyle says that she experienced the gap firsthand in what’s available to women beyond what her obstetrician or midwife does.

“You had to work really hard to cobble together the care you needed. It was a matter of putting together my personal experiences of realizing it’s not just me, it’s systematic,” says Doyle. “I couldn’t get that problem out of my head.”

Neither could her co-founder and head of operations, Matt Rogers, a father of twins whose family had to navigate the NICU and life-threatening complications. They started working together on the business in earnest during the COVID shutdown and debuted Partum Health at the beginning of 2021.

Partum has begun partnering with obstetricians and midwives to help select complementary care that includes lactation support, pelvic floor physical therapy, mental health services, nutrition counseling and doula care. What’s unique about the plan is that, from aiding in behavioral health problems to addressing nutritional issues, the user’s team is distributed around the Houston area and are fully virtual. Physical therapy and other services that must be done in-person may take place either in-home or at third-party locations.

“We’re still in the process of credentialing with insurance companies,” says Doyle.

In Illinois, Partum is already working with BlueCross BlueShield, United Healthcare, Aetna and Cigna for clinical care, so Doyle says she is confident that those companies will soon follow suit in Texas.

While hiring a team in Houston that includes a client care lead, Doyle says that Partum is simultaneously providing services and getting to know the market better. They’re also building more bundled models of care to better assist users in their new landscape.

Doyle and Partum Healthcare participated in the Ignite Healthcare Network’s 2023 program, which concluded last week with a pitch competition. Ignite helps female healthcare founders to connect with mentors and other industry experts that will help them navigate the health tech ecosystem. Doyle was one of nine finalists, but did not place in the top three. But she says the program has helped prepare her for success nonetheless.

“In our world, you’re always pitching,” she admits.

The next steps for Partum include a 2024 rife with expansion. Because building relationships with insurance happens on a state-by-state basis, the company will be able to help women around Texas soon after the company is comfortably established in Houston. The Dallas-Fort Worth area will likely be first, followed by Austin and San Antonio.

“We know there’s a huge gap in access to care that may mean evolving a little bit and reaching out across the state,” Doyle says.

Last month, the Texas Health and Human Services Commission reported that 90 percent of the state’s pregnancy-related deaths are preventable. With access to care like what Partum provides, those complications could become a thing of the past.

A Houston founder is introducing you to ema — a GPT-based chat platform and your new best friend in women's health. Photo via Canva

Exclusive: Houston startup rebrands to provide AI chat tool focused on women’s health

meet ema

Amanda Ducach set out to create a platform where mothers could connect with each other socially, but when she launched SocialMama just ahead of a global pandemic, she soon learned there was a bigger market need for access to information surrounding women's health — from fertility to menopause.

After pivoting her femtech platform to include women's health experts, she realized her technology wasn't able to completely support growing user base. The platform, which was called SocialMama, saw users engaging with experts in similar ways — and as Ducach looked into growing the platforms users, she realized that 24/7 access to experts was going to be hard to scale.

"We noticed that most of these conversations were repetitive," Ducach tells InnovationMap. "You had women asking an expert about tracking ovulation a hundred times a day. Having an OBGYN answer that question a hundred times a day was crazy and just not scalable."

Ducach says that about 16 months ago, her team took a step back to recreate the platform incorporating GPT technology. GPT stands for generative pre-trained transformer, and is a family of artificial intelligence language models most recently made popular but ChatGPT developed by OpenAI.

Now, after building out the platform, Ducach's company has rebranded to ema. The AI-based chat tool — named from the three letters in the middle of "female" — is meant to feel like texting "your childhood best friend who became an OBGYN physician," Ducach says. Not only can the chat provide crucial medical information, but it has a memory and can pick up conversations where they left off to be a constant resource to users.

The new platform, deemed ema, operates as an AI-based chat for women to engage with. Screenshot courtesy of ema

"Ema can answer everything from, 'how do I improve my baby's latch,' to 'how to I get a diabetic-friendly brownie recipe,' to 'give me an affirmation that's spoken like Snoop Dog because I'm feeling sad today,'" Ducach says.

Ducach first described the evolution of the company to AI-based communication last summer on the Houston Innovators Podcast. Now, the platform is gearing up for its launch next month and plans to raise seed funding this year to double her current team of 10 people to support the company's growth. Ducach, who was accepted into the Techstars Austin program in 2021, also says she's looking for more beta users in the meantime, and those interested should reach out to her or her team.

Ultimately, Ducach says the mission of ema is to democratize access to women's health care so that women feel supported and just a few taps away from important information.

"Barriers to care for women who face socioeconomic disparities is where you see the need for change," Ducach says. "For us, it's reducing those barriers of care. Ema is always in your pocket. You have access to her 24/7. The way that ema is really structured and her purpose is to catch red flags so that we can then help the female user get to positive health outcomes."

Amanda Ducach founded the company in 2019. Photo via Twitter

Houston-based Work & Mother is growing. Photo courtesy of Work & Mother

Houston-based femtech company announces first locations outside of Texas

growing tech

Houston-based Work & Mother, which outfits commercial buildings with lactation accommodations for working parents, announced this month that it has entered into an agreement to open two new lactation suites outside the state of Texas.

The company will open suites in two commercial office buildings in Boston, Massachusetts, and Arlington, Virginia, just outside of Washington, D.C. The new suites are expected to be completed this summer.

Work & Mother currently has suites in Allen Center, The Jones on Main and Four Oaks Place in Houston, as well as East Lake at Tillery in Austin and Lincoln Centre in Dallas.

The Work & Mother suites allow parents to book time to pump in a private room in the comfortable, well-designed suites through the Work & Mother app. Each private room is equipped with a hospital-grade pump, milk storage bags, sanitizing wipes, and other supplies while the full Work & Mother Suite lounge area includes cleaning stations and refrigerated milk storage.

The suites also serve commercial properties and employers by providing them with the resources to adhere to federal labor laws—as well as reduce HR risks, and retain female employees—by having a dedicated space with lactation amenities for employees.

When founder and CEO Abby Donnell spoke with InnovationMap in 2021, she said that Work & Mother was planning for national expansion.

"We look forward to supporting more new mothers' return to work and providing the real estate services that office tenants and landlords need in a post-pandemic world to promote wellness, flexibility, and inclusion in the workplace," she said.

In addition to the new location in Boston and Arlington, the company is planning locations in San Francisco, Chicago, Miami and New York, according to Work & Mother's website.

The company is also adding new services for working and lactating parents through a recent partnership with Nest Collaborative, a national virtual lactation consultation platform, announced last month.

The partnership will provide Work & Mother app users with access to Nest Collaborative's board-certified lactation consultants through telehealth appointments, available seven days a week.

The services through Nest Collaborative are part of Work & Mother's resource center called The HUB, which also provides career and personal coaching, mental health resources, and downloadable guides.

"We are confident that our partnership with Nest Collaborative will have a measurable impact on the breastfeeding success rates of parents who work outside the home," Donnell said in a statement. "I'm looking forward to broadening our ability to support working parents at any time, anywhere."

Kyra Doolan joins the Houston Innovators Podcast to discuss the huge opportunities for innovation within femtech. Photo via LinkedIn

Houston investor shares why she's focused on funding the future of femtech

HOUSTON INNOVATORS PODCAST EPISODE 98

Successful investors find gaps in the marketplace and direct funds into startups and technologies resolving those gaps. For Kyra Doolan, managing director at Houston-based Texas HALO Fund, femtech represents a huge opportunity for innovation.

"A lot of the issues that face women, are things that are not talked about," she says on this week's episode of the Houston Innovators Podcast, referencing things like miscarriage, injury during childbirth, etc. "For a lot time, women just sat back if they had these issues, and they kept it to themselves, so those problems weren't being addressed."

While Texas HALO Fund has invested in femtech since its first fund in 2012, Doolan shares on the show how she personally saw an investment opportunity with kegg, a fertility tracking device. Doolan says she and other women aren't taught how to manage their own fertility journey, but it doesn't have to be that way.

"I was at a stage in my life where my eyes were open to the gaps that are out there and the conversations that weren't being had," she says. "In looking into Kegg, it showed me what the market was and how many gapes there were in the market just around fertility."

Texas HALO Fund has a few femtech companies in its portfolio now, and the most recent addition is Houston-based Work & Mother, a company that builds out fully-equipped nursing accommodations in office buildings.

Despite it's growing femtech portfolio, the fund is industry agnostic, though, Doolan says, about a third of the companies Texas HALO Fund invests in reside in the health tech space. What makes HALO different is its focus on early-stage startups.

"We like to get in early," Doolan says. "We're, what you would historically consider 'pre-VC,' but now that's getting a little bit blurred. ... We're some of the earlier capital that's invested, and we continue to make investment as the companies continue to subsequent rounds."

Doolan shares more on her passion for femtech, as well as her advice for founders looking for funding and potential female investors looking to get into investing on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


One way to move the needle on developing femtech, according to this expert, is to make sure women have a seat at the table at venture firms funding the innovations. Photo via Getty Images

The growing femtech industry needs more attention — and funds, says this Houston expert

guest column

Femtech is a term that is generally given to medical products, software, and technologies that aim to enhance the health and wellbeing of women. But when people think of femtech, things like period tracker apps and pregnancy tests are usually the first things to come to mind. While those developments are important and used regularly, there are other diseases and chronic issues affecting women that need to be talked about as well.

The concept of femtech shouldn't replace "women's health" which considers broader issues, such as endometriosis and PCOS, as well as other conditions — such as heart disease — common to both men and women but clinically different in the latter. Femtech investors, manufacturers, and health advocates should focus on creating solutions for all issues and diseases that affect women, not just the most obvious.

However, more education and awareness is necessary to bring these issues to the forefront, as many people are not aware about how certain chronic issues and diseases affect women differently than they may affect men. For example, heart disease is the leading cause of death in women and men, but if you close your eyes and envision someone having a heart attack — do you see a man? Or a woman? Probably a man. And you're not alone. Because so much of our healthcare research has focused primarily on men, we are programmed to think of certain conditions affecting men predominantly when they are truly major health issues for both.

Similarly, when it comes to memory loss, women have a 1 in 5 chance of developing Alzheimer's disease compared to men being 1 in 11. Additionally, out of the more than 5 million people living with Alzheimer's in the U.S., 3.2 million are women. While there aren't as many Femtech-related products or solutions focused on these issues, there should be, especially in a rapidly growing industry.

According to the U.S. Clinical Laboratory Test Market, the femtech industry is expected to grow at a compound annual growth rate of more than 13 percent. Frost and Sullivan predicts the global Femtech market revenue will reach $1.1 billion by 2024, and BIS Research forecasts that by 2030 the sector will hit $3.04 billion. But even with great momentum, there is a knowledge gap that needs to be bridged. Overall, the industry has been underfunded and many opportunities have been overlooked, not necessarily because of gender. But, because investors in the industry are predominantly men, there is a lack of education and understanding of why these products are needed.

A solution would be for more women to become investors. Women have the personal experience and a better understanding of how these products will benefit them, which allows them to better understand the story told, increasing the chance the product will be funded and brought to market. To fund life-changing inventions for women, we need to have women involved, which means we need women to step into the investment community. Until more women get a seat at the investment table, women in femtech who are looking for investors need to be prepared to share real life stories and provide as much information as possible to have a better chance of securing funding.

The femtech industry is growing, and we will continue to see innovative devices and apps brought to market. With more education, a better understanding of other issues that affect women, and more female investors, the industry has the potential to take its growth to a new level.

------

Isabella Schmitt currently serves as the director of regulatory affairs at Proxima Clinical Research Inc.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston cleantech, space startups named to World Economic Forum cohort

top honor

Two Houston-based startups have been selected to join the World Economic Forum's Technology Pioneers community.

The two-year program aims to help mission-driven, early-stage start-ups scale their innovations through multi-stakeholder initiatives, co-creating partnerships and other gatherings for community members. One-hundred startups are selected each year from around the globe, this year hailing from 23 countries and working in AI, energy, space, biotech markets and more.

Cleantech startup Vaulted Deep was one of 11 energy and climate companies to be named to the cohort. Julia Reichelstein and Omar Abou-Sayed founded the company in 2023. Its technology injects excess organic waste underground to remove carbon dioxide from the atmosphere.

Last year, Vaulted Deep inked a 12-year deal with Microsoft to remove up to 4.9 million metric tons of carbon dioxide from the environment.

The startup has earned several accolades in recent years, including a No. 3 spot on Fast Company’s list of the World’s Most Innovative Companies of 2026. It was also recently named to market intelligence and advisory firm Cleantech Group's annual Global Cleantech 100 list for a second year in a row.

"Waste management is one of the world's great invisible infrastructure systems ... The need for new infrastructure is growing as disposal challenges become more complex and regulations evolve. Vaulted is building the first new disposal pathway for organic waste in decades by putting it deep underground, permanently," the company shared in a LinkedIn post. "This year, we're joining the World Economic Forum's 2026 Tech Pioneers alongside innovators working on the many interconnected challenges shaping our future."

Houston-based Venus Aerospace was also selected to join the cohort, along with six other spacetech companies. The company was founded in 2020 by Sassie and Andrew Duggleby.

The startup specializes in next-generation rocket engine propulsion as a cleaner alternative to traditional combustion engines. The company's rotating detonation rocket engine (RDRE) burns fuel more efficiently and completed a successful high-thrust test flight last year. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

"Frontier technologies matter most when they expand what people, industries, and nations can do," Sassie Duggleby, co-founder and CEO of Venus, said in a news release. "For Venus, RDRE does not just represent a more efficient engine. It is a foundation for faster movement, more capable space systems, and new forms of connectivity across the planet. Being named a Technology Pioneer validates the potential of this technology to help shape a future where distance is less limiting."

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”